Assurea Blog: Computer System Validation, GxP Compliance & AI Insights for Biotech, Pharma & Medical Device Teams

AI manufacturing intelligence dashboard for technology transfer and batch record review

AI Manufacturing Intelligence for Technology Transfer: Reducing Manual Master Batch Record Reviews

How AI-powered document analytics helps manufacturing teams compare complex documentation, identify process differences, and accelerate technology transfer while keeping GMP decisions under human oversight. Technology Transfer Is Still a Documentation-Intensive Process Successful technology transfer is about far more than moving a manufacturing process from one facility to another. It requires ensuring that manufacturing knowledge is

Read More
Illustration representing eQMS selection considerations for biotech companies

Validation of Veeva Vault Quality for a Global CDMO

How Assurea validated a U.S. deployment of Veeva Vault Quality and established a reusable validation framework for future global site rollouts. Project Overview When a global Contract Development and Manufacturing Organization (CDMO) selected Veeva Vault Quality to standardize its quality management processes, the first deployment was planned for a U.S. manufacturing site located on the

Read More
AI-assisted QMS alignment after a biotech acquisition

Reducing Post-Acquisition QMS Integration Effort with AI 

How Assurea helped a biotechnology company assess and align site vs global QMS following an acquisition using AI-assisted analytics and expert quality review. Project Overview Following the acquisition of a biotechnology company, our client needed to understand how the acquired site’s Quality Management System (QMS) aligned with its global quality framework before beginning integration activities.

Read More
Shared responsibility between vendor and regulated company in SaaS validation

Who Owns What in SaaS Validation? Vendor vs Regulated Company Responsibilities

Many life sciences organizations commonly ask this question when implementing a SaaS platform: “If the vendor already validated the system, what do we still need to do?” The answer is straightforward. The vendor is responsible for the platform it develops, operates, and maintains. The regulated company remains responsible for how that platform is configured, governed,

Read More
Defining intended use for AI and SaaS tools in pharma

How to Define Intended Use for AI and SaaS Tools in Pharma

Defining intended use is one of the most important steps in validating AI and SaaS tools in regulated pharma and biotech environments. The intended use statement establishes validation scope, testing strategy, risk classification, supplier oversight expectations, and procedural controls. For AI systems, this is often more difficult than traditional software because operational usage can evolve

Read More
Digital validation of interconnected systems in a life sciences facility

Validating Interfaces & Data Flows: Essential for Digital Validation in Life Sciences

In today’s digital biotech environment, labs and manufacturing sites rely on a complex network of interconnected systems: LIMS, QMS, MES, ERP, CDS, eBMRs, data historians, and analytics platforms. While each system may be validated independently, the movement of data between them is where the highest risk now lives. Regulators increasingly expect organizations to demonstrate end-to-end

Read More
MSAT staffing supporting a pharma technology transfer to the EU

Case Study: MSAT Staffing to Support a U.S.–to–EU Pharma Technology Transfer

Background: A Late-Stage Biopharma Preparing for EU Commercialization A mid-sized U.S.-based biopharmaceutical company was preparing to commercialize its first biologic product in the European Union. As part of its global expansion strategy, the company initiated a technology transfer from its U.S. clinical manufacturing facility to a commercial EU site (located in Ireland). While the company

Read More
AI-driven summarization of supplier audit data for a biotech company

Case Study: AI-Driven Supplier Audit Data Summarization

Turning Supplier Audit Files into Actionable Insights for a Mid-Size Biotech Introduction A mid-size biotech organization with approximately 600 employees and a single GMP manufacturing site faced a common challenge: hundreds of supplier audit reports, self-assessment questionnaires, and CAPA summaries stored across multiple folders, but no easy way to extract trends or prioritize risks. The

Read More
Staffing support for a biotech site expansion project

Case Study: Accelerating a Biotech Site Expansion with Assurea’s Staffing Expertise

Client: A Biotech CompanyIndustry: Life Sciences / Pharmaceutical ManufacturingSize: 150–200 employeesEngagement Type: Full-service contract staffing partnershipPartner: Assurea Background A rapidly growing biotech company specializing in cell and gene therapy recently secured Series C funding to expand its manufacturing capacity. The organization planned to establish a new biomanufacturing site in New Jersey, aimed at scaling production

Read More